Protein Kinase Inhibitors: all 15,278 studies that test it

Page 96 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2
• Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male SubjectsCompletedNCT04171310Phase 1
• Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)CompletedNCT04170556Phase 1/2
• A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibActive, not recruitingNCT04170283Phase 3
• Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisStatus unknownNCT04170179Phase 2
• Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Active, not recruitingNCT04170153Phase 1
• Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid TumorsCompletedNCT04169672Phase 2
• Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular CarcinomaStatus unknownNCT04168944Phase 2/3
• KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic ImpairmentCompletedNCT04166942Phase 1
• Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsActive, not recruitingNCT04165330Phase 1/2
• Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerStatus unknownNCT04164745Phase 2
• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3
• Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without BevacizumabCompletedNCT04164069Phase 1
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy MalesCompletedNCT04163783Phase 1
• Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy SubjectsCompletedNCT04163523Phase 1
• A Study of CS3002 in Subjects With Advanced Solid TumorsTerminatedNCT04162301Phase 1
• A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Phase 3
• The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment TrialStatus unknownNCT04161014Phase 2
• Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)CompletedNCT04160546Phase 2
• A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneStatus unknownNCT04158947Phase 2
• Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast CancerActive, not recruitingNCT04158362Phase 3
• A Study of Azenosertib (ZN-c3) in Participants With Solid TumorsCompletedNCT04158336Phase 1
• Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed GlioblastomaStatus unknownNCT04157478Phase 2
• Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCCStatus unknownNCT04157140Phase 2
• Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract AdenocarcinomaStatus unknownNCT04156958Phase 2
• Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
• Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CPStatus unknownNCT04155411Phase 4
• Effect and Safety of Apatinib on Radiation-Induced Brain InjuryStatus unknownNCT04152681Phase 2
• Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast CancerStatus unknownNCT04152057Phase 1/2
• Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2
• Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian CancerWithdrawnNCT04149145Phase 1
• Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04148898Phase 2
• Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)WithdrawnNCT04148742Phase 1/2
• Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLCStatus unknownNCT04147728Phase 2
• Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid LeukemiaActive, not recruitingNCT04147533Phase 2
• SHR0302 and Steroid As First Line Therapy for Chronic GVHDCompletedNCT04146207Early Phase 1
• A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditionsCompletedNCT04145570Phase 4
• Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal AdenocarcinomasCompletedNCT04145297Phase 1
• ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingNCT04143607Phase 3
• A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsCompletedNCT04143477Phase 1
• Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast CancerWithdrawnNCT04142554Phase 1
• Tofacitinib in Depression (TIDE)TerminatedNCT04141904Phase 1/2
• Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCActive, not recruitingNCT04141644Phase 1
• Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the ElderlyWithdrawnNCT04139915Phase 3
• Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)Active, not recruitingNCT04138381Phase 1/2
• A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711CompletedNCT04135820Phase 1
• A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female ParticipantsCompletedNCT04134715Phase 1
• Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR StudyCompletedNCT04134390Phase 2
• Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic CancerCompletedNCT04132505Phase 1
• To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive MutationStatus unknownNCT04132102Phase 4
• Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT04131738Phase 1
• Phase II Study With Cabozantinib in Patients With RET Positive NSCLCStatus unknownNCT04131543Phase 2
• Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic CancerTerminatedNCT04131192Phase 1
• Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant ChemotherapyCompletedNCT04130152Early Phase 1
• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsCompletedNCT04129502Phase 3
• Appatinib Combined With S-1 in the Treatment of Small Cell Lung CancerStatus unknownNCT04128800Phase 2
• Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeActive, not recruitingNCT04128748Phase 1/2
• TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUNCompletedNCT04128722Phase 2
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant TumorsStatus unknownNCT04128085Phase 1
• Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell TransplantationWithdrawnNCT04127721Phase 2
• Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTTStatus unknownNCT04127396Phase 4
• Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC PatientsActive, not recruitingNCT04127110Phase 2
• Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue SarcomaStatus unknownNCT04126811Phase 2
• The Absorption, Metabolism and Excretion of [14C] HQP1351 in HumansCompletedNCT04126707Phase 1
• A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT04126681Phase 2
• Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast CancerActive, not recruitingNCT04126525Phase 2
• Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCompletedNCT04125693Phase 2
• Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)Status unknownNCT04124731Phase 2
• A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With ItraconazoleCompletedNCT04121910Phase 1
• MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's DiseaseTerminatedNCT04121208Phase 1
• Study of the Apatinib Combine With POF Versus POF in Gastric CancerStatus unknownNCT04121039Phase 2
• Ruxolitinib as a Salvage Therapy for Hemophagocytic LymphohistiocytosisStatus unknownNCT04120090Phase 3
• Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaCompletedNCT04118855Phase 2
• A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With RifampicinCompletedNCT04118842Phase 1
• Abemaciclib + Pembrolizumab In GlioblastomaWithdrawnNCT04118036Phase 2
• Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
• Liposomal Sirolimus in Dry Eye DiseaseCompletedNCT04115800Early Phase 1
• A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT04115631Phase 2
• Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast CancerActive, not recruitingNCT04115306Phase 1/2
• The Effects Diflunisal on the Levels of BMS-986165 in Healthy ParticipantsCompletedNCT04113668Phase 1
• A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
• A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung CancerStatus unknownNCT04111913Phase 2
• Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung CancerCompletedNCT04111705Phase 2
• A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.CompletedNCT04111614Phase 1
• Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal CancerStatus unknownNCT04110093Phase 1/2
• IN10018 Monotherapy and Combination Therapy for Metastatic MelanomaCompletedNCT04109456Phase 1
• A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaStatus unknownNCT04108325Phase 1
• Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)CompletedNCT04107727Phase 2
• A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory NeuroblastomaActive, not recruitingNCT04106219Phase 1
• Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter TrialStatus unknownNCT04106024Phase 2
• Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With VitiligoCompletedNCT04103060Phase 2
• Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG RegimenStatus unknownNCT04101929Phase 2
• Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy ParticipantsCompletedNCT04099563Phase 1
• Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male SubjectsCompletedNCT04098692Phase 1
• A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667CompletedNCT04097938Phase 1
• Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS PatientsActive, not recruitingNCT04097470Phase 2
• A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast CancerStatus unknownNCT04095390Phase 2
• Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the DrugCompletedNCT04095273Phase 1
• A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and RhabdomyosarcomaCompletedNCT04095221Phase 1/2
• Sirolimus for Cowden Syndrome With Colon PolyposisCompletedNCT04094675Phase 2

← Protein Kinase Inhibitors overview